CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 16, 2017, Charles J. Cashion tendered his resignation as Senior Vice President, Finance, Chief Financial Officer and Secretary of Conatus Pharmaceuticals Inc. (the “Company”), a position which he has held since co-founding the Company in 2005. The resignation will be effective on March 31, 2017, and he will continue to serve as Senior Vice President, Finance, Chief Financial Officer and Secretary until that date, during which time the Company expects to complete its year-end audit and file its Annual Report on Form 10-K. Mr. Cashion plans to retire and his decision to resign from the Company did not result from any disagreement with the Company concerning any matter relating to its operations, policies or practices.

About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Recent Trading Information

CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) closed its last trading session up +0.03 at 5.25 with 248,931 shares trading hands.